Listed

BioNTech SE: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Mar 20, 2024 and accepted by EDGAR at Mar 20, 2024, 07:57 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31EUR 3.82bnifrs-full:RevenueFromContractsWithCustomers
Cost of revenue12 months2023-01-01 to 2023-12-31EUR 599.8mifrs-full:CostOfSales
Operating income12 months2023-01-01 to 2023-12-31EUR 690.4mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2023-01-01 to 2023-12-31EUR 255.8mifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-01-01 to 2023-12-31EUR 930.3mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2023-01-01 to 2023-12-31EUR 3.83ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-01-01 to 2023-12-31EUR 3.87ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-01-01 to 2023-12-31EUR 5.37bnifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31EUR 249.4mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2023-12-31EUR 11.66bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2023-12-31EUR 19.53bnifrs-full:CurrentAssets
Total assetsAt period end2023-12-31EUR 23.01bnifrs-full:Assets
Current liabilitiesAt period end2023-12-31EUR 2.07bnifrs-full:CurrentLiabilities
Total liabilitiesAt period end2023-12-31EUR 2.76bnifrs-full:Liabilities
Shareholders' equityAt period end2023-12-31EUR 20.25bnifrs-full:Equity

Source: SEC EDGAR, the filing index for accession 0001776985-24-000027. Last ingested by Listed: Nov 10, 2026, 16:47 ET. Listed shows no prices and gives no investment advice.